“…Fosmidomycin ( 1 ), a phosphonate antibiotic with a hydroxamate pharmacophore that was originally isolated from Streptomyces lavendulae , , is known to have antibacterial and herbicidal activity and was more recently shown to be active against the Plasmodium species causing malaria. , Its molecular target, IspC, catalyzes the first committed step in the non-mevalonate isoprenoid biosynthesis pathway that is essential in Plasmodium spp. but absent in mammals (Scheme ). , 1 can cure human malaria and has a favorable toxicity profile but has shortcomings with regard to pharmacokinetic aspects, which prompted structural modifications in several laboratories. − Also of note, 1 and its analogs are expected to be exempt from target-related toxicity and from cross-resistance with established antimalarials and may even be able to target the malaria liver stages that are insufficiently addressed by current antimalarials. , We report the synthesis of thia isosters of reversed hydroxamic acid analogs of 1 and their enzymatic, antiparasite, and structural biology features. Furthermore, we show that IspC has a high degree of enantioselectivity for a reverse α-aryl derivative of 1 .…”